Company: STAA
Filing Date: 2025-10-02
Form Type: DFAN14A
Source: 0001213900-25-095514
Chunk: 18

Company: STAAR SURGICAL CO
Filing Date: 2025-10-02
Form: DFAN14A
Chunk 18
---
 $44 $45 $46 $63 $65 $66 $69 $71 $73 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25 Americas EMEA 1. Source: STAAR Quarterly Reports on Form 10 - Q for the applicable periods. 2. Source: William Blair Growth Stock Conference, June 4, 2025. 3. Source: STAAR Q4 2024 Earnings Call, February 11, 2025. 2 B

Broadwood Partners, L.P. U.S. ICL Unit vs. Refractive Market Growth 1 …And ICLs Have Outpaced the Broader Refractive Market… 26 STAAR’s U.S. business is modest, but it is growing significantly faster than the U.S. refractive market overall ▪ STAAR believes, as we do, that the future of refractive surgery is lens - based (vs. laser/LASIK) and that ICL procedures will continue to grow over time with increased awareness and adoption 2 ▪ Management believes the total addressable market for lens - based refractive vision correction is a much bigger opportunity than laser - based procedures 2 ▪ We agree with management that there is an opportunity – through surgeon education and product innovation – to expand STAAR’s addressable market further by moving “down the diopter curve” and reaching patients with lower levels of myopia 3 — The lead investigator of a forthcoming study recently stated that STAAR’s EVO+ ICLs are an effective procedure for patients at a lower diopter range, 4 which we believe could have significant implications for the competitive positioning of ICLs – which have historically been seen as a niche product – relative to LASIK in the U.S. ▪ Growth achieved to date reflects the significant value that STAAR’s ICL solutions provide to both patients and providers, according to management, 5 and demonstrates that STAAR’s commercial strategies in the U.S., including increased professional education, practice development, and clinical application support, are working 5 18% 36% 63% 109% 78% 10% 6% (12%) 13% 27% 19% 30% (9%) (15%) (7%) (10%) (9%) (15%) (15%) (16%) (21%) (16%) (18%) (18%) (50%) (25%) 0%